16 MARCH 2018 VOLUME 19 ISSUE 11

Public health leaders in the fight against HIV/AIDS have come to an ominous realization: Progress in cutting new infections has slowed, in part because of a persistent cycle of transmission among young women in sub-Saharan Africa.

Preliminary findings from a new open-label study of a vaginal ring infused with an anti-HIV drug show the vast majority of women use the device at least once, though plenty of questions remain about just how effective a tool the device will be, and for whom.

New research says the country is making considerable progress in the fight against HIV/AIDS, as new infections decreased by 39%.

I have spent the last four years researching the invisibility of women with HIV/AIDS as part of my PhD, in which I examine the art of the American AIDS crisis.

Peter Sands took over this month as the new head of the Global Fund to Fight AIDS, Tuberculosis and Malaria...he was under attack for a new partnership with Heineken. Health advocates said alcohol is a major risk factor for the spread of HIV and TB. They also said alcohol adversely affects development efforts such as "poverty eradication, health for all, gender equality, economic prosperity, sustainable consumption, ending violence and building safer and resilient cities."

A decade and billions of dollars later, Desrosiers’s criticism still looms large: "Are human-vaccine trials the best use of resources?" In Africa, the question is particularly acute in the face of declining resources.

The World Health Organization’s Initiative for Vaccine Research (IVR) organized a meeting of researchers, activists, and policymakers in Geneva, Switzerland, to discuss strategies for ensuring that a viable HIV vaccine, once developed, would reach the very people who would benefit most from it.

The fight against HIV/AIDS has registered significant milestones. The latest figures from Rwanda Biomedical Centre (RBC) show that the mother-to-child HIV transmission rate reduced from 1.83 percent in 2013/2014 to 1.51 percent in 2016/17.

A drug-resistant strain of the HIV virus discovered in the Philippines has the potential to spark a new epidemic, scientists have warned. Researchers are concerned a new drug-resistant version of the virus, HIV subtype AE, could be fuelling the epidemic.

In HIV-infected women, chronic HBV infection, mostly treated using targeted ART, had no major impact on the course of pregnancy. By contrast, chronic HCV infection was associated with a higher risk of obstetrical complications and a poorer immune–virological response to ART.

Programme managers need to demonstrate that the scale up of differentiated ART delivery is achieving the desired effectiveness and efficiency outcomes to justify continued support by national and global stakeholders.

Globally, the population of adolescents living with perinatally acquired HIV (APHs) continues to expand. In this study, we pooled data from observational pediatric HIV cohorts and cohort networks, allowing comparisons of adolescents with perinatally acquired HIV in “real-life” settings across multiple regions.